Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Haematologica|September 2, 2004
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groupsSergio Amadori, Stefan Suciu, Roel Willemze, et al.Frontiers in Immunology|July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic LeukemiaAnnika Nelde, Yacine Maringer, Tatjana Bilich, et al.The Lancet. Haematology|December 16, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialMoshe Mittelman, Uwe Platzbecker, Boris Afanasyev, et al.BMC Cancer|August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trialClemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)Arndt Stahler, Dominik P Modest, Ludwig Fischer von Weikersthal, et al.Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.International Journal of Cancer|December 13, 2025
Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)Thorsten O Goetze, Salah-Eddin Al-Batran, Ruediger Liersch, et al.Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)Kathrin Heinrich, Dominik P Modest, Ingrid Ricard, et al.European Journal of Cancer (Oxford, England : 1990)|September 10, 2021
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)Arndt Stahler, Volker Heinemann, Veronika Schuster, et al.Pageof 3